Adjuvant Erlotinib in Lung Cancer Prolongs Disease-Free Survival

(MedPage Today) -- No recurrence 2 years after surgery in almost 90% of EGFR+ NSCLC patients
Source: MedPage Today Primary Care - Category: Primary Care Source Type: news